PharmaJet announced Vaccibody AS has received approval to start their cancer neoantigen trial using the PharmaJet Stratis needle-free injection system.
Vaccibody, a clinical-stage biopharmaceutical company focused on the development of novel immunotherapies, is a leader in the rapidly developing field of individualized therapeutic cancer vaccines targeting solid tumors. In this personalized medicine approach, each patient receives a unique DNA vaccine with up to 20 neoepitopes delivered by the PharmaJet Stratis needle-free device, in combination with standard of care checkpoint inhibitor therapy. The individualized medicine will be tested in patients with locally advanced or metastatic non-small cell lung cancer, melanoma, renal, bladder or head and neck cancer.
"We are pleased that Vaccibody has again chosen our PharmaJet Stratis device to deliver their personalized cancer neoantigen vaccine due to its positive effect on their previous DNA based HPV vaccine candidate," said Ron Lowy, Chairman and Chief Executive Officer, PharmaJet. "We continue to be proud to be part of the pharmaceutical industry's focus on treating multiple types of cancer. This is another example of how our needle-free devices are helping novel DNA technologies move successfully from pre-clinical studies into early and late stage clinical trials."